» Articles » PMID: 38596493

Overview of the Immunological Mechanisms in Hepatitis B Virus Reactivation: Implications for Disease Progression and Management Strategies

Overview
Specialty Gastroenterology
Date 2024 Apr 10
PMID 38596493
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis B virus (HBV) reactivation is a clinically significant challenge in disease management. This review explores the immunological mechanisms underlying HBV reactivation, emphasizing disease progression and management. It delves into host immune responses and reactivation's delicate balance, spanning innate and adaptive immunity. Viral factors' disruption of this balance, as are interactions between viral antigens, immune cells, cytokine networks, and immune checkpoint pathways, are examined. Notably, the roles of T cells, natural killer cells, and antigen-presenting cells are discussed, highlighting their influence on disease progression. HBV reactivation's impact on disease severity, hepatic flares, liver fibrosis progression, and hepatocellular carcinoma is detailed. Management strategies, including anti-viral and immunomodulatory approaches, are critically analyzed. The role of prophylactic anti-viral therapy during immunosuppressive treatments is explored alongside novel immunotherapeutic interventions to restore immune control and prevent reactivation. In conclusion, this comprehensive review furnishes a holistic view of the immunological mechanisms that propel HBV reactivation. With a dedicated focus on understanding its implications for disease progression and the prospects of efficient management strategies, this article contributes significantly to the knowledge base. The more profound insights into the intricate interactions between viral elements and the immune system will inform evidence-based approaches, ultimately enhancing disease management and elevating patient outcomes. The dynamic landscape of management strategies is critically scrutinized, spanning anti-viral and immunomodulatory approaches. The role of prophylactic anti-viral therapy in preventing reactivation during immunosuppressive treatments and the potential of innovative immunotherapeutic interventions to restore immune control and proactively deter reactivation.

Citing Articles

Human immune system: Exploring diversity across individuals and populations.

Hoang Nguyen K, Le N, Nguyen P, Nguyen H, Hoang D, Huynh C Heliyon. 2025; 11(2):e41836.

PMID: 39911431 PMC: 11795082. DOI: 10.1016/j.heliyon.2025.e41836.


Contradictory Mechanisms of rheumatoid arthritis and hepatitis B virus infection activation.

Zhu F, Wang M, Zhang X, Zhao G, Gao H, Zhou L Heliyon. 2025; 11(1):e41444.

PMID: 39850429 PMC: 11755052. DOI: 10.1016/j.heliyon.2024.e41444.

References
1.
de Almeida Ponde R . Detection of the serological markers hepatitis B virus surface antigen (HBsAg) and hepatitis B core IgM antibody (anti-HBcIgM) in the diagnosis of acute hepatitis B virus infection after recent exposure. Microbiol Immunol. 2021; 66(1):1-9. DOI: 10.1111/1348-0421.12943. View

2.
Xu H, Locarnini S, Wong D, Hammond R, Colledge D, Soppe S . Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A. J Hepatol. 2021; 76(1):34-45. DOI: 10.1016/j.jhep.2021.07.031. View

3.
Liu K, Wang F, Xu R . Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cell Mol Immunol. 2020; 18(1):38-44. PMC: 7852892. DOI: 10.1038/s41423-020-00560-0. View

4.
Kim S, Yoon J, Lee M, Cho Y . Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus. Clin Mol Hepatol. 2021; 28(1):17-30. PMC: 8755466. DOI: 10.3350/cmh.2021.0093. View

5.
Cacoub P, Asselah T . Hepatitis B Virus Infection and Extra-Hepatic Manifestations: A Systemic Disease. Am J Gastroenterol. 2021; 117(2):253-263. DOI: 10.14309/ajg.0000000000001575. View